company background image
CRVS

Corvus Pharmaceuticals NasdaqGM:CRVS Stock Report

Last Price

US$1.02

Market Cap

US$47.5m

7D

14.0%

1Y

-67.1%

Updated

04 Dec, 2022

Data

Company Financials +
CRVS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CRVS Stock Overview

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.

Corvus Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Corvus Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.02
52 Week HighUS$3.41
52 Week LowUS$0.69
Beta0.94
1 Month Change18.06%
3 Month Change12.34%
1 Year Change-67.10%
3 Year Change-76.28%
5 Year Change-90.35%
Change since IPO-92.84%

Recent News & Updates

Recent updates

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Shareholder Returns

CRVSUS BiotechsUS Market
7D14.0%4.2%1.5%
1Y-67.1%-7.4%-14.9%

Return vs Industry: CRVS underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: CRVS underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is CRVS's price volatile compared to industry and market?
CRVS volatility
CRVS Average Weekly Movement9.1%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: CRVS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CRVS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201428Rick Millerhttps://www.corvuspharma.com

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.

Corvus Pharmaceuticals, Inc. Fundamentals Summary

How do Corvus Pharmaceuticals's earnings and revenue compare to its market cap?
CRVS fundamental statistics
Market CapUS$47.48m
Earnings (TTM)-US$40.73m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRVS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$40.73m
Earnings-US$40.73m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.87
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CRVS perform over the long term?

See historical performance and comparison